After BioNTech’s acquisition of CureVac closes, BioNTech will pay GSK another $130 million and a 1% royalty on rest-of-world ...

Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. BioNTech SE is conducting a ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

BioNTech reaches agreement to get a non-exclusive license for mRNA-based Covid-19 and/or influenza products and resolve patent litigation with CureVac & GSK: Mainz, Germany Monday ...

Parents in the United States who want to vaccinate their young children against Covid-19 this fall may face a growing set of ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 ...

BioNTech has agreed to pay UK drugmaker GSK royalties on its Covid-19 and influenza vaccines as part of a patent settlement with CureVac, in a deal that allows the biotech to move forward with the ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...